Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Men
NCT05847439Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-986419 in amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration, Time of maximum plasma observed concentration and 4 more. Started May 2023; status: completed.
02
Drugs
BMS-986419
03
Conditions
amyotrophic lateral sclerosis (ALS)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05847439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05847439.